As mentioned in the present manuscript, hosts with higher expression of MCM2 might be more susceptible to MDS‐type myeloid neoplasms while MCM2‐low hosts have a higher risk of developing AML or MPN when genetic mutations occur in hematopoietic stem cells. The gene discussed is MCM2; the disease is myeloproliferative neoplasm.